2f:I[703058,["/_next/static/immutable/chunks/2esyeua7r8hxb.js","/_next/static/immutable/chunks/43wzqu_q6b8co.js","/_next/static/immutable/chunks/02igegklyi312.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/3d54cr_x61503.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/41sb2pnxui1_7.js","/_next/static/immutable/chunks/0z5fu495o1bws.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T9e5,The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs). To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs. In this case-time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)-α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024. The initiation of the biologic was screened in both periods. The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator. Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change. In this case-time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded.31:Tf24, Importance The cardiovascular impact of biologics used in psoriasis is not fully understood. Several studies have suggested that the inhibition of the T-helper 17 cell pathway could lead to the destabilization of atherosclerotic plaques, leading to major adverse cardiovascular events (MACEs). Objective To assess whether the initiation of interleukin (IL)-17(R)A inhibitors triggers MACEs. Design, Setting, and Participants In this case–time-control study using the French National Health Insurance database, all individuals who received IL-17(R)A inhibitors (secukinumab, ixekizumab, and brodalumab) from 2016 to 2021, were included and classified according to their cardiovascular risk level. The risk period was defined as the 6 months before the MACE, and the reference period as the 6 months before the risk period. The same design for patients who received tumor necrosis factor (TNF)–α inhibitors (adalimumab or etanercept) for similar indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an active comparator. The data analysis was conducted between April 2023 and August 2024. Exposure The initiation of the biologic was screened in both periods. Main Outcomes and Measures The odds ratios (ORs) for the risk of MACEs were assessed following the initiation of IL-17(R)A inhibitors and TNF-α inhibitors independently. Subsequently, the OR for the risk of MACE associated with IL-17(R)A inhibitors was estimated using TNF-α inhibitors as the comparator. Results Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk ( P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change. Conclusions In this case–time-control study based on a national insurance database, there was no evidence of a significant association between MACEs and the initiation of IL-17(R)A inhibitors, regardless of the individual cardiovascular risk of the patient. However, a modest risk increase cannot be entirely excluded. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Taltz in Dermatology: Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed Dermatology papers on Taltz (brand). Clinician-written summaries and practical action steps. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/Dermatology/brand/Taltz\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Dermatology Hub\",\"item\":\"https://www.reachrx.ai/hub/Dermatology\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"brand: Taltz\",\"item\":\"https://www.reachrx.ai/hub/Dermatology/brand/Taltz\"}]}}"}}]],["$","$L2f",null,{"title":"Taltz in Dermatology Research","description":"See Dermatology clinical studies on Taltz — efficacy, safety signals, dosing, and head-to-head results.","papers":[{"doi":"10.2340/actadv.v106.adv-2026-0797","pmid":"42708646","title":"Current Evidence on IL-17 and IL-(12)/23 Inhibitor Safety during Pregnancy in Psoriasis: A Call for Harmonized Data Collection","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-09-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0797","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-12T06:20:17.230Z","updated_at":"2026-09-12T06:20:17.230Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Bimzelx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Skyrizi","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Stelara","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"brand","value":"Tremfya","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"bimekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"guselkumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"mirikizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"risankizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"tildrakizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"generic","value":"ustekinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-12/23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"modality","value":"IL-23 Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sample_size","value":"n=5962","value_numeric":5962},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"study_design","value":"Systematic Review","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Level of evidence assigned as 3 (systematic review of heterogeneous, mostly observational studies); no meta-analysis was conducted due to methodological heterogeneity.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"Sex tag set to 'female' as the primary dataset covers maternal exposure; paternal exposure studies also exist but are a small subset (3 studies, 281 pregnancies).","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The review included all indications for IL inhibitors (not psoriasis-only), so findings may not be fully generalizable to psoriasis patients specifically.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0797","tag_type":"warning","value":"The sample size (n=5,962) reflects maternal pregnancy exposures across all included studies, not a single trial cohort; the majority originated from pharmacovigilance databases with inherent reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A PRISMA-compliant systematic literature review (search date May 2026) evaluated the reproductive safety of IL-12/23, IL-17, and IL-23 inhibitors during pregnancy and with paternal exposure in patients with psoriasis, examining pregnancy and neonatal outcomes across all available study designs.","key_result":"49 publications met inclusion criteria, reporting 5,962 pregnancies with maternal exposure; ustekinumab had the most data (2,933 pregnancies), followed by secukinumab (1,877), risankizumab (589), ixekizumab (296), guselkumab (217), tildrakizumab (32), bimekizumab (11), brodalumab (6), and mirikizumab (1). Cohort-level findings were generally reassuring — no consistent signal for adverse pregnancy or neonatal outcomes — except one study reporting increased risk of small-for-gestational-age infants with ustekinumab. Paternal exposure data were very limited (3 studies, 281 pregnancies).","limitations":"- Most exposures (n=5,074) came from pharmacovigilance databases that capture only adverse events, making incidence rates incalculable and meta-analysis infeasible.\n- Critical confounders (disease activity, exposure timing, comedications) were missing or unreported in the majority of studies; only one study used confounder-adjusted analysis.\n- Data were heavily skewed toward IBD patients, limiting psoriasis-specific and IL-17-specific conclusions.","practice_takeaway":"Available data are broadly reassuring but insufficient to issue definitive safety guidance; clinicians should weigh uncontrolled disease risk against medication uncertainty on a case-by-case basis. Existing psoriasis registries (e.g., BADBIR, BioCAPTURE) should add standardized pregnancy datasets to accelerate evidence generation."}},{"doi":"10.2340/actadv.v106.adv-2026-0461","pmid":"42257527","title":"Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-06-08T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0461","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:43.016Z","updated_at":"2026-06-10T14:24:43.016Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Erythrodermic Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Generalized Pustular Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"modality","value":"IL-17A Inhibitor","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"sample_size","value":"n=23","value_numeric":23},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"All authors have disclosed financial relationships with multiple pharmaceutical companies, including Eli Lilly (ixekizumab manufacturer), which may introduce bias.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"ARR definition relied on clinical records from a single centre, with potential for ascertainment variability.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0461","tag_type":"warning","value":"Very small sample size (n=23) produces highly imprecise odds ratios (e.g., 95% CI 1.41–192.00); findings should be considered hypothesis-generating only.","value_numeric":null}],"summaries":{"what_studied":"This single-centre retrospective study examined risk factors for administration-related reactions (ARRs) to the modified (citrate-free) ixekizumab formulation in 23 psoriasis patients treated between January 2023 and December 2025.","key_result":"7 of 23 patients (30.4%) developed ARRs; 6 of those 7 had switched from secukinumab. Multivariate logistic regression showed prior secukinumab use was significantly associated with ARRs (OR 16.40, 95% CI 1.41–192.00, p=0.03). All ARRs were grade 1; 4 women discontinued ixekizumab due to intolerable reactions.","limitations":"Very small sample size (n=23) from a single centre limits generalisability; wide confidence intervals reflect imprecision; no mechanistic data to confirm causal pathway between prior secukinumab use and ARRs.","practice_takeaway":"When switching psoriasis patients from secukinumab to ixekizumab, counsel them about a higher likelihood of injection-site reactions, even with the newer citrate-free formulation. Monitor closely after the first dose and have a contingency plan if reactions are intolerable."}},{"doi":"10.1001/jamadermatol.2026.1753","pmid":"42139049","title":"Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1753","source_score":15,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-18T13:25:20.466Z","updated_at":"2026-05-18T13:25:20.466Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"brand","value":"Zepbound","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Overweight","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"condition","value":"Plaque Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"modality","value":"GIP/GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"modality","value":"IL-17A Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"sample_size","value":"n=274","value_numeric":274},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"Level of evidence tagged as '2' rather than '1' due to open-label (non-blinded) design despite randomization.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"Open-label design (not blinded) is a notable methodological limitation that the authors acknowledge; objective endpoints like PASI may be less prone to bias, but weight-related outcomes could be influenced.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1753","tag_type":"warning","value":"The trial is ongoing (52-week endpoint not yet reported); results here reflect the week 36 primary endpoint only.","value_numeric":null}],"summaries":{"what_studied":"Phase 3b RCT (n=274) evaluating ixekizumab + tirzepatide vs. ixekizumab alone (both with diet and exercise) over 52 weeks in adults with moderate-to-severe plaque psoriasis and overweight/obesity (mean BMI 39.2) at 72 US sites; primary endpoint assessed at week 36.","key_result":"At week 36, 27.1% on combination therapy vs. 5.8% on ixekizumab alone simultaneously achieved PASI 100 and ≥10% weight loss (RD 21.2%; 95% CI 12.8%–29.7%; P<.001). PASI 100 alone: 40.6% vs. 29.0% (P=.04). ≥10% weight reduction: 69.2% vs. 9.1% (RD 60.0%). GI adverse events were more common in the combination arm.","limitations":"Open-label design may introduce assessment bias. The trial was conducted exclusively at US sites, limiting generalizability. Week 52 data were not yet available at the time of analysis.","practice_takeaway":"For patients with moderate-to-severe psoriasis and obesity, adding tirzepatide to ixekizumab produces substantially greater skin clearance and weight loss than ixekizumab alone, with no new safety signals. Clinicians should counsel patients on higher rates of GI side effects with the combination."}},{"doi":"10.1001/jamadermatol.2026.1694","pmid":"42139041","title":"Targeting Cardiometabolic Disease to Improve Psoriasis—A New Treatment Paradigm Emerges","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.1694","source_score":14,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-18T13:25:20.020Z","updated_at":"2026-05-18T13:25:20.020Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"brand","value":"Mounjaro","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"condition","value":"Cardiometabolic Disease","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"modality","value":"GLP-1/GIP Receptor Agonist","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"study_design","value":"Editorial / Commentary on Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"warning","value":"Brand name 'Mounjaro' listed for tirzepatide reflects its obesity/diabetes indication branding; the editorial does not specify a brand name.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"warning","value":"No sample size for the TOGETHER-PsO trial is reported in this editorial; the sample_size tag has been omitted accordingly.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"warning","value":"Several authors report financial relationships with manufacturers of relevant drugs (Novo Nordisk, Lilly, AbbVie, Johnson & Johnson, Pfizer, others), which should be considered when interpreting the editorial framing.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1694","tag_type":"warning","value":"This is an editorial commentary, not the primary trial report — specific trial data (e.g., PASI 100 rates, metabolic outcomes) are cited from the TOGETHER-PsO trial paper (Lebwohl et al., JAMA Dermatol 2026) and cannot be fully verified from this text alone.","value_numeric":null}],"summaries":{"what_studied":"This editorial discusses the TOGETHER-PsO phase 3b trial, which added tirzepatide (GLP-1/GIP agonist) to ixekizumab (IL-17 biologic) vs. ixekizumab alone in adults with moderate-to-severe psoriasis and overweight/obesity over 36 weeks, and argues for a new cardiometabolic treatment paradigm in psoriasis.","key_result":"At week 36, 40.6% of patients on ixekizumab + tirzepatide achieved PASI 100 vs. 29.0% on ixekizumab alone (P = .04); 27.1% vs. 5.8% met the composite primary endpoint of PASI 100 plus ≥10% weight loss (P < .001). The combination also reduced triglycerides by ~30 mg/dL and systolic blood pressure by ~10 mm Hg.","limitations":"- Trial was open-label with no placebo control, making skin benefit estimates imprecise and potentially biased.\n- Skin improvement was a secondary endpoint, limiting the strength of that inference.\n- It is unclear whether benefit came from tirzepatide's direct anti-inflammatory effects, weight loss, or improved ixekizumab pharmacokinetics.","practice_takeaway":"Dermatologists treating moderate-to-severe psoriasis in patients with overweight or obesity should screen routinely for cardiometabolic risk factors (BP, HbA1c, lipids, BMI) and consider collaborative care with cardiologists or obesity specialists. Adding tirzepatide to IL-17 biologic therapy may improve both skin clearance and cardiovascular risk factors simultaneously."}},{"doi":"10.1001/jamadermatol.2025.2972","pmid":"40900466","title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-09-03T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.2972","source_score":13,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-21","doi":"10.1001/jamadermatol.2025.2972","days":"7","issn":"2168-6068","rank":"10","field":"Clinical Medicine","score":"13","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.2972","title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.","journal":"JAMA dermatology","methods":"","results":"Among the 34 241 individuals who received an IL-17(R)A inhibitor, 381 MACEs were analyzed, including 176 acute coronary syndromes and 84 ischemic strokes in the main analysis. Initiation of IL-17(R)A inhibitors was not significantly associated with MACEs (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitor initiation and MACEs: OR, 0.90 [95% CI, 0.65-1.24]). Overall, the initiation of an IL-17(R)A inhibitor was not significantly associated with MACEs in the following 6 months, using TNF-α inhibitor as a comparator (OR, 1.40 [95% CI, 0.77-2.54]), regardless of the individual cardiovascular risk (P for homogeneity = .29). The definition of MACE was broadened in a first sensitivity analysis, and the risk period was shortened to 3 months in a second sensitivity analysis. The results did not change.","abstract":"$30","keywords":[],"pubmed_id":"40900466","conclusions":"","publication_date":"2025-09-03T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.2972","URL":"https://doi.org/10.1001/jamadermatol.2025.2972","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2838219/jamadermatology_raby_2025_oi_250041_1762976601.59148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1107","type":"journal-article","issue":"11","score":1,"title":["Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events"],"author":[{"given":"Maxime","family":"Raby","sequence":"first","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]},{"given":"Frederic","family":"Balusson","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes Hospital, France"}]},{"given":"Emmanuel","family":"Oger","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes Hospital, France"}]},{"given":"Marion","family":"Gundelwein","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]},{"given":"Florence","family":"Poizeau","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)—UMR_S 1085, Rennes, France"},{"name":"Department of Dermatology, Université de Rennes, CHU Rennes, Rennes, France"}]}],"issued":{"date-parts":[[2025,11,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-09-03T15:00:28Z","timestamp":1756911628000,"date-parts":[[2025,9,3]]},"indexed":{"date-time":"2025-11-19T16:04:21Z","timestamp":1763568261864,"date-parts":[[2025,11,19]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2838219"}},"subtitle":[],"deposited":{"date-time":"2025-11-19T16:00:39Z","timestamp":1763568039000,"date-parts":[[2025,11,19]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1093/eurheartj/ehr285","key":"doi250041r1","year":"2012","issue":"16","author":"Ahlehoff","volume":"33","first-page":"2054","unstructured":null,"article-title":"Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-020-01346-6","key":"doi250041r2","year":"2020","issue":"5","author":"Masson","volume":"37","first-page":"2017","unstructured":null,"article-title":"Psoriasis and cardiovascular risk: a comprehensive review.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/ehp567","key":"doi250041r3","year":"2010","issue":"8","author":"Mehta","volume":"31","first-page":"1000","unstructured":null,"article-title":"Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1038/jid.2009.446","key":"doi250041r4","year":"2010","issue":"4","author":"Stern","volume":"130","first-page":"917","unstructured":null,"article-title":"Psoriasis is not a useful independent risk factor for cardiovascular disease.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamacardio.2024.2859","key":"doi250041r5","year":"2024","issue":"11","author":"Ramessur","volume":"9","first-page":"1009","unstructured":null,"article-title":"Exploring the link between genetic predictors of cardiovascular disease and psoriasis.","journal-title":"JAMA Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.4433","key":"doi250041r6","year":"2024","issue":"1","author":"Svedbom","volume":"161","first-page":"81","unstructured":null,"article-title":"Skin inflammation, systemic inflammation, and cardiovascular disease in psoriasis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.det.2018.07.004","key":"doi250041r7","year":"2019","issue":"1","author":"Kim","volume":"37","first-page":"29","unstructured":null,"article-title":"Biologics and psoriasis: the beat goes on.","journal-title":"Dermatol Clin","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/ket303","key":"doi250041r8","year":"2005","issue":"7","author":"Jacobsson","volume":"32","first-page":"1213","unstructured":null,"article-title":"Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.","journal-title":"J Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.110.214585","key":"doi250041r9","year":"2011","issue":"3","author":"Di Minno","volume":"31","first-page":"705","unstructured":null,"article-title":"Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-a blockers and traditional disease-modifying antirheumatic drugs.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2796.2012.02593.x","key":"doi250041r10","year":"2013","issue":"2","author":"Ahlehoff","volume":"273","first-page":"197","unstructured":null,"article-title":"Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.","journal-title":"J Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1001/archdermatol.2012.2502","key":"doi250041r11","year":"2012","issue":"11","author":"Wu","volume":"148","first-page":"1244","unstructured":null,"article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.","journal-title":"Arch Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2011.10525.x","key":"doi250041r12","year":"2011","issue":"5","author":"Abuabara","volume":"165","first-page":"1066","unstructured":null,"article-title":"The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2019.0001","key":"doi250041r13","year":"2019","issue":"6","author":"Lee","volume":"155","first-page":"700","unstructured":null,"article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18964","key":"doi250041r14","year":"2023","issue":"7","author":"Salahuddin","volume":"37","first-page":"e862","unstructured":null,"article-title":"Biologic therapy for psoriasis is associated with reduced risk of death: Insights from the VA clinical assessment, reporting and tracking program.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.2147/PTT.S328575","key":"doi250041r15","year":"2022","issue":null,"author":"Al-Janabi","volume":"12","first-page":"1","unstructured":null,"article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management.","journal-title":"Psoriasis (Auckl)","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250041r16","year":"2015","issue":"7","author":"Papp","volume":"14","first-page":"706","unstructured":null,"article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).","journal-title":"J Drugs Dermatol","doi-asserted-by":null},{"DOI":"10.1038/jid.2011.304","key":"doi250041r17","year":"2012","issue":"2","author":"Gordon","volume":"132","first-page":"304","unstructured":null,"article-title":"A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate to severe psoriasis.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/S2665-9913(23)00120-0","key":"doi250041r18","year":"2023","issue":"9","author":"Papp","volume":"5","first-page":"e542","unstructured":null,"article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.","journal-title":"Lancet Rheumatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2011.1211","key":"doi250041r19","year":"2011","issue":"8","author":"Ryan","volume":"306","first-page":"864","unstructured":null,"article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.12126","key":"doi250041r20","year":"2013","issue":"12","author":"Tzellos","volume":"27","first-page":"1586","unstructured":null,"article-title":"Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1505066","key":"doi250041r21","year":"2015","issue":"26","author":"Baeten","volume":"373","first-page":"2534","unstructured":null,"article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1412679","key":"doi250041r22","year":"2015","issue":"14","author":"Mease","volume":"373","first-page":"1329","unstructured":null,"article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljad039","key":"doi250041r23","year":"2023","issue":"6","author":"Egeberg","volume":"188","first-page":"793","unstructured":null,"article-title":"Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bcp.15581","key":"doi250041r24","year":"2023","issue":"8","author":"Woods","volume":"89","first-page":"2386","unstructured":null,"article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).","journal-title":"Br J Clin Pharmacol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijcard.2024.131819","key":"doi250041r25","year":"2024","issue":null,"author":"Al-Yafeai","volume":"402","first-page":null,"unstructured":null,"article-title":"Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS).","journal-title":"Int J Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamacardio.2024.2868","key":"doi250041r26","year":"2024","issue":"11","author":"Garshick","volume":"9","first-page":"961","unstructured":null,"article-title":"Psoriasis and atherosclerotic CV disease—risk factor or risk marker?","journal-title":"JAMA Cardiol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.2977","key":"doi250041r27","year":"2020","issue":"11","author":"Poizeau","volume":"156","first-page":"1208","unstructured":null,"article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/rheumatology/keab522","key":"doi250041r28","year":"2022","issue":"4","author":"Pina Vegas","volume":"61","first-page":"1589","unstructured":null,"article-title":"Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study.","journal-title":"Rheumatology (Oxford)","doi-asserted-by":"publisher"},{"DOI":"10.3389/fimmu.2019.03096","key":"doi250041r29","year":"2020","issue":null,"author":"von Stebut","volume":"10","first-page":"3096","unstructured":null,"article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications.","journal-title":"Front Immunol","doi-asserted-by":"publisher"},{"DOI":"10.1093/cvr/cvz009","key":"doi250041r30","year":"2019","issue":"4","author":"Elnabawi","volume":"115","first-page":"721","unstructured":null,"article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study.","journal-title":"Cardiovasc Res","doi-asserted-by":"publisher"},{"DOI":"10.3390/biomedicines11020318","key":"doi250041r31","year":"2023","issue":"2","author":"Tsiogka","volume":"11","first-page":"318","unstructured":null,"article-title":"The impact of treatment with IL-17/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and/or psoriatic arthritis: a systematic review.","journal-title":"Biomedicines","doi-asserted-by":"publisher"},{"DOI":"10.1093/eurheartj/ehs263","key":"doi250041r32","year":"2013","issue":"8","author":"Simon","volume":"34","first-page":"570","unstructured":null,"article-title":"Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction.","journal-title":"Eur Heart J","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.114.303567","key":"doi250041r33","year":"2015","issue":"2","author":"Taleb","volume":"35","first-page":"258","unstructured":null,"article-title":"IL-17 and Th17 cells in atherosclerosis: subtle and contextual roles.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1161/CIRCRESAHA.122.320263","key":"doi250041r34","year":"2022","issue":"12","author":"Gisterå","volume":"130","first-page":"1869","unstructured":null,"article-title":"Animal models of atherosclerosis-supportive notes and tricks of the trade.","journal-title":"Circ Res","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.atherosclerosis.2021.09.024","key":"doi250041r35","year":"2021","issue":null,"author":"Lutgens","volume":"335","first-page":"98","unstructured":null,"article-title":"Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies.","journal-title":"Atherosclerosis","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.4233","key":"doi250041r36","year":"2017","issue":"8","author":"Bezin","volume":"26","first-page":"954","unstructured":null,"article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12874-021-01440-5","key":"doi250041r37","year":"2021","issue":"1","author":"Bosco","volume":"21","first-page":"241","unstructured":null,"article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review.","journal-title":"BMC Med Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.therap.2023.01.009","key":"doi250041r38","year":"2023","issue":"6","author":"de Germay","volume":"78","first-page":"679","unstructured":null,"article-title":"Performing pharmacoepidemiological studies using the French health insurance data warehouse (SNDS): how to translate guidelines into practice.","journal-title":"Therapie","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16566","key":"doi250041r39","year":"2021","issue":"2","author":"Grodner","volume":"35","first-page":"411","unstructured":null,"article-title":"Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1159/000438859","key":"doi250041r40","year":"2015","issue":"1-2","author":"Giroud","volume":"74","first-page":"92","unstructured":null,"article-title":"Positive predictive value of French hospitalization discharge codes for stroke and transient ischemic attack.","journal-title":"Eur Neurol","doi-asserted-by":"publisher"},{"DOI":"10.1097/00001648-199505000-00010","key":"doi250041r41","year":"1995","issue":"3","author":"Suissa","volume":"6","first-page":"248","unstructured":null,"article-title":"The case–time-control design.","journal-title":"Epidemiology","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJM199312023292301","key":"doi250041r42","year":"1993","issue":"23","author":"Mittleman","volume":"329","first-page":"1677","unstructured":null,"article-title":"Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(97)11084-4","key":"doi250041r43","year":"1998","issue":"9114","author":"Meier","volume":"351","first-page":"1467","unstructured":null,"article-title":"Acute respiratory-tract infections and risk of first-time acute myocardial infarction.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.1996.03530420033032","key":"doi250041r44","year":"1996","issue":"18","author":"Muller","volume":"275","first-page":"1405","unstructured":null,"article-title":"Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1093/oxfordjournals.aje.a115853","key":"doi250041r45","year":"1991","issue":"2","author":"Maclure","volume":"133","first-page":"144","unstructured":null,"article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events.","journal-title":"Am J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1093/aje/kwab110","key":"doi250041r46","year":"2021","issue":"10","author":"Hallas","volume":"190","first-page":"2181","unstructured":null,"article-title":"The use of active comparators in self-controlled designs.","journal-title":"Am J Epidemiol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250041r47","year":"2015","issue":"1/2","author":"Hashemi-Nazari","volume":"1","first-page":"59","unstructured":null,"article-title":"Case-crossover and case–time-control studies: concepts, design, and analysis.","journal-title":"J Biostat Epidemiol","doi-asserted-by":null},{"DOI":"10.1093/ije/dyu081","key":"doi250041r48","year":"2014","issue":"5","author":"Mittleman","volume":"43","first-page":"1645","unstructured":null,"article-title":"Exchangeability in the case-crossover design.","journal-title":"Int J Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1136/annrheumdis-2021-222027","key":"doi250041r49","year":"2022","issue":"7","author":"Deodhar","volume":"81","first-page":"944","unstructured":null,"article-title":"Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.","journal-title":"Ann Rheum Dis","doi-asserted-by":"publisher"},{"DOI":"10.1161/ATVBAHA.111.229997","key":"doi250041r50","year":"2012","issue":"2","author":"Danzaki","volume":"32","first-page":"273","unstructured":null,"article-title":"Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice.","journal-title":"Arterioscler Thromb Vasc Biol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.16273","key":"doi250041r51","year":"2020","issue":"8","author":"Egeberg","volume":"34","first-page":"1695","unstructured":null,"article-title":"The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13075-023-03257-7","key":"doi250041r52","year":"2024","issue":"1","author":"Deodhar","volume":"26","first-page":"49","unstructured":null,"article-title":"Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.","journal-title":"Arthritis Res Ther","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v102.563","key":"doi250041r53","year":"2022","issue":null,"author":"Gottlieb","volume":"102","first-page":null,"unstructured":null,"article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1186/s13075-019-1882-2","key":"doi250041r54","year":"2019","issue":"1","author":"Deodhar","volume":"21","first-page":"111","unstructured":null,"article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.","journal-title":"Arthritis Res Ther","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20128","key":"doi250041r55","year":"2025","issue":"3","author":"Poizeau","volume":"39","first-page":"447","unstructured":null,"article-title":"Biologics targeting interleukin (IL)-23 and the risk of cardiovascular events: where are we?","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.publhealth.21.1.193","key":"doi250041r56","year":"2000","issue":null,"author":"Maclure","volume":"21","first-page":"193","unstructured":null,"article-title":"Should we use a case-crossover design?","journal-title":"Annu Rev Public Health","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.5031","key":"doi250041r57","year":"2020","issue":"9","author":"Bykov","volume":"29","first-page":"1079","unstructured":null,"article-title":"Bias in case-crossover studies of medications due to persistent use: a simulation study.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.5490","key":"doi250041r58","year":"2022","issue":"10","author":"Rasmussen","volume":"31","first-page":"1015","unstructured":null,"article-title":"Core concepts in pharmacoepidemiology: measures of drug utilization based on individual-level drug dispensing data.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.3389/fmed.2024.1353893","key":"doi250041r59","year":"2024","issue":null,"author":"Zhang","volume":"11","first-page":null,"unstructured":null,"article-title":"Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials.","journal-title":"Front Med (Lausanne)","doi-asserted-by":"publisher"},{"DOI":"10.7759/cureus.60980","key":"doi250041r60","year":"2024","issue":"5","author":"Ni","volume":"16","first-page":null,"unstructured":null,"article-title":"The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials.","journal-title":"Cureus","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2020.01.025","key":"doi250041r61","year":"2020","issue":"9","author":"Gelfand","volume":"140","first-page":"1784","unstructured":null,"article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S).","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2018.02.074","key":"doi250041r62","year":"2018","issue":"1","author":"Egeberg","volume":"79","first-page":"104","unstructured":null,"article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40744-022-00434-z","key":"doi250041r63","year":"2022","issue":"3","author":"Merola","volume":"9","first-page":"935","unstructured":null,"article-title":"Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications.","journal-title":"Rheumatol Ther","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2018.10.042","key":"doi250041r64","year":"2019","issue":"5","author":"von Stebut","volume":"139","first-page":"1054","unstructured":null,"article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,11,1]]},"reference-count":64,"published-online":null,"references-count":64,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.2972","is_oa":false,"title":"Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events","updated":"2025-09-04T02:50:00+00:00","published_date":"2025-09-03","best_oa_location":null}},"created_at":"2025-11-23T07:03:49.856Z","updated_at":"2025-11-28T07:01:22.464Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Cosentyx","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Enbrel","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Humira","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Siliq","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"brand","value":"Taltz","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Ankylosing Spondylitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Juvenile Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"condition","value":"Psoriatic Arthritis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"adalimumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"brodalumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"etanercept","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"ixekizumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"generic","value":"secukinumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"modality","value":"IL-17 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"modality","value":"TNF-Alpha Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"sample_size","value":"n=34,241","value_numeric":34241},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"study_design","value":"Case-Time-Control Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Abstract reports odds ratios without absolute event rates by exposure group.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Design labeled as case–time–control; classification may be unfamiliar to some readers.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.2972","tag_type":"warning","value":"Only early (3–6 month) risk windows were evaluated; longer-term risk remains uncertain.","value_numeric":null}],"summaries":{"what_studied":"A national case–time–control study of the French health insurance database (2016–2021) assessed whether initiating IL‑17(R)A inhibitors (secukinumab, ixekizumab, brodalumab) triggers major adverse cardiovascular events (MACEs) within 6 months, using TNF‑α inhibitors (adalimumab, etanercept) as an active comparator. Among 34,241 IL‑17(R)A recipients, 381 MACEs were analyzed; risk and reference windows were the 6 months before the MACE and the preceding 6 months.","key_result":"Initiation of IL‑17(R)A inhibitors was not significantly associated with MACEs (OR 1.25, 95% CI 0.75–2.08); TNF‑α inhibitor initiation also showed no association (OR 0.90, 95% CI 0.65–1.24). Compared with TNF‑α inhibitors, IL‑17(R)A initiation had an OR of 1.40 (95% CI 0.77–2.54) over 6 months, with similar findings across cardiovascular risk strata (P for homogeneity = .29) and unchanged results in sensitivity analyses (broader MACE definition; 3‑month risk window).","limitations":"Only early risk windows (3–6 months) were evaluated, so longer‑term risk was not assessed. Precision was limited by 381 MACEs, yielding wide confidence intervals that do not exclude a modest risk increase.","practice_takeaway":"In this large real‑world analysis, starting an IL‑17(R)A inhibitor did not show a significant increase in 6‑month MACEs versus TNF‑α inhibitors, across cardiovascular risk levels. Continue standard cardiovascular risk management; a small increase in early events cannot be ruled out."}}],"initialOffset":5,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"category","value":"Dermatology"},{"tag_type":"brand","value":"Taltz"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Dermatology","href":"/hub/Dermatology"},{"name":"brand: Taltz","metadata":{"type":"brand","value":"Taltz"}}],"hrefConfig":{"basePath":"/hub/Dermatology/papers","webViewQueryParams":{"hub_ctx":"category_tag","hub_category":"Dermatology","hub_tag_type":"brand","hub_tag_value":"Taltz"}}}]]

Papers